Search

Pharming Group NV

Abrir

1.176 0.86

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.157

Máximo

1.185

Indicadores-chave

By Trading Economics

Rendimento

19M

4.7M

Vendas

14M

93M

EPS

0.006

Margem de lucro

5.035

Funcionários

404

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+104.38% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

276M

893M

Abertura anterior

0.32

Fecho anterior

1.176

Pharming Group NV Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de out. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20 de out. de 2025, 23:43 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de out. de 2025, 23:36 UTC

Conversa de Mercado

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20 de out. de 2025, 22:14 UTC

Conversa de Mercado

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20 de out. de 2025, 22:00 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20 de out. de 2025, 21:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20 de out. de 2025, 20:56 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 de out. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

20 de out. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

20 de out. de 2025, 20:38 UTC

Ganhos

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20 de out. de 2025, 20:38 UTC

Ganhos

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20 de out. de 2025, 20:38 UTC

Ganhos

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20 de out. de 2025, 20:16 UTC

Conversa de Mercado

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20 de out. de 2025, 20:05 UTC

Ganhos

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20 de out. de 2025, 19:39 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20 de out. de 2025, 19:34 UTC

Conversa de Mercado

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20 de out. de 2025, 19:32 UTC

Conversa de Mercado

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20 de out. de 2025, 19:00 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 de out. de 2025, 18:29 UTC

Conversa de Mercado

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20 de out. de 2025, 18:11 UTC

Conversa de Mercado

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20 de out. de 2025, 18:04 UTC

Conversa de Mercado

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20 de out. de 2025, 17:03 UTC

Conversa de Mercado

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20 de out. de 2025, 17:01 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de out. de 2025, 17:01 UTC

Conversa de Mercado

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20 de out. de 2025, 16:43 UTC

Conversa de Mercado

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20 de out. de 2025, 16:25 UTC

Conversa de Mercado

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Pharming Group NV Previsão

Preço-alvo

By TipRanks

104.38% parte superior

Previsão para 12 meses

Média 2.453 EUR  104.38%

Máximo 2.45 EUR

Mínimo 2.45 EUR

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Pharming Group NV - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
help-icon Live chat